Evaluation of Antibody-Dependent Enhancement of SARS-CoV Infection in Rhesus Macaques Immunized with an Inactivated SARS-CoV Vaccine - PubMed (original) (raw)
Evaluation of Antibody-Dependent Enhancement of SARS-CoV Infection in Rhesus Macaques Immunized with an Inactivated SARS-CoV Vaccine
Fan Luo et al. Virol Sin. 2018 Apr.
No abstract available
Conflict of interest statement
Conflict of interest
The authors declare that they have no conflict of interest to disclose.
Animal and Human Rights Statement
All of the study protocols and procedures were approved by the Institutional Animal Care and Use Committee of Wuhan University.
Figures
Fig. 1
Low levels of neutralizing antibodies induced by the inactivated vaccine SARS-CoV Z-1 do not trigger ADE following the challenge. A Rhesus macaques were immunized intramuscularly with 2.5 μg beta-propiolactone-inactivated whole SARS-CoV Z-1 vaccine or PBS as control, and boosted on day 7. The blood was collected at 0, 4, 6, 7, 8, 9 weeks post-immunization. Titers were expressed as the reciprocal of the dilution at which 50% of the plaques reduced completely in the virus-wells. Data were presented as the mean ± S.E. for each group. B On day 10 or 14 post-infection, the surviving monkeys from the three groups were euthanized and necropsied; the lungs were collected and fixed using 4% formaldehyde, sectioned, and subjected to hematoxylin and eosin staining. Magnification, ×200. The arrows refer to the widening of alveolar septa and the infiltration of inflammatory cells. C The nasopharyngeal swabs were collected on day 2 post-challenge. The presence of SARS-CoV polymerase gene in the swabs was confirmed by RT-PCR. No. 1, 2, 3, 4, 8, 9, 10, and 11 lanes are from immunized group; No. 7, 12, 15, and 16 lanes are from virus control group; No. 5, 6, 13, 14 lanes are the swabs from negative control group; M, molecular size marker; PC, purified virus as positive control; NC, without cDNA template. D The virus titers of the sera from the monkeys whose samples showed positive results in virus isolation were detected on days 5 and 7 post-challenge by TCID50. The values of the titer were expressed directly by the calculated number.
Similar articles
- Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection.
Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H, Tang H, Nishiura K, Peng J, Tan Z, Wu T, Cheung KW, Chan KH, Alvarez X, Qin C, Lackner A, Perlman S, Yuen KY, Chen Z. Liu L, et al. JCI Insight. 2019 Feb 21;4(4):e123158. doi: 10.1172/jci.insight.123158. eCollection 2019 Feb 21. JCI Insight. 2019. PMID: 30830861 Free PMC article. - Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine.
Qin E, Shi H, Tang L, Wang C, Chang G, Ding Z, Zhao K, Wang J, Chen Z, Yu M, Si B, Liu J, Wu D, Cheng X, Yang B, Peng W, Meng Q, Liu B, Han W, Yin X, Duan H, Zhan D, Tian L, Li S, Wu J, Tan G, Li Y, Li Y, Liu Y, Liu H, Lv F, Zhang Y, Kong X, Fan B, Jiang T, Xu S, Wang X, Li C, Wu X, Deng Y, Zhao M, Zhu Q. Qin E, et al. Vaccine. 2006 Feb 13;24(7):1028-34. doi: 10.1016/j.vaccine.2005.06.038. Epub 2005 Sep 12. Vaccine. 2006. PMID: 16388880 Free PMC article. - Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates.
Wang Q, Zhang L, Kuwahara K, Li L, Liu Z, Li T, Zhu H, Liu J, Xu Y, Xie J, Morioka H, Sakaguchi N, Qin C, Liu G. Wang Q, et al. ACS Infect Dis. 2016 May 13;2(5):361-76. doi: 10.1021/acsinfecdis.6b00006. Epub 2016 Apr 11. ACS Infect Dis. 2016. PMID: 27627203 Free PMC article. - Studies of SARS virus vaccines.
Zheng BJ, Du LY, Zhao GY, Lin YP, Sui HY, Chan C, Ma S, Guan Y, Yuen KY. Zheng BJ, et al. Hong Kong Med J. 2008 Aug;14 Suppl 4:39-43. Hong Kong Med J. 2008. PMID: 18708674 Review. - SARS vaccines: where are we?
Roper RL, Rehm KE. Roper RL, et al. Expert Rev Vaccines. 2009 Jul;8(7):887-98. doi: 10.1586/erv.09.43. Expert Rev Vaccines. 2009. PMID: 19538115 Free PMC article. Review.
Cited by
- Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection.
Winkler ES, Gilchuk P, Yu J, Bailey AL, Chen RE, Chong Z, Zost SJ, Jang H, Huang Y, Allen JD, Case JB, Sutton RE, Carnahan RH, Darling TL, Boon ACM, Mack M, Head RD, Ross TM, Crowe JE Jr, Diamond MS. Winkler ES, et al. Cell. 2021 Apr 1;184(7):1804-1820.e16. doi: 10.1016/j.cell.2021.02.026. Epub 2021 Feb 12. Cell. 2021. PMID: 33691139 Free PMC article. - Equine immunoglobulin fragment F(ab')2 displays high neutralizing capability against multiple SARS-CoV-2 variants.
Gupta D, Ahmed F, Tandel D, Parthasarathy H, Vedagiri D, Sah V, Krishna Mohan B, Khan RA, Kondiparthi C, Savari P, Jain S, Reddy S, Kumar JM, Khan N, Harshan KH. Gupta D, et al. Clin Immunol. 2022 Apr;237:108981. doi: 10.1016/j.clim.2022.108981. Epub 2022 Mar 17. Clin Immunol. 2022. PMID: 35306171 Free PMC article. - Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains.
Padron-Regalado E. Padron-Regalado E. Infect Dis Ther. 2020 Jun;9(2):255-274. doi: 10.1007/s40121-020-00300-x. Epub 2020 Apr 23. Infect Dis Ther. 2020. PMID: 32328406 Free PMC article. Review. - Vaccine-associated enhanced disease in humans and animal models: Lessons and challenges for vaccine development.
Bigay J, Le Grand R, Martinon F, Maisonnasse P. Bigay J, et al. Front Microbiol. 2022 Aug 10;13:932408. doi: 10.3389/fmicb.2022.932408. eCollection 2022. Front Microbiol. 2022. PMID: 36033843 Free PMC article. Review. - Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target.
Hong J, Jhun H, Choi YO, Taitt AS, Bae S, Lee Y, Song CS, Yeom SC, Kim S. Hong J, et al. Immune Netw. 2021 Feb 19;21(1):e8. doi: 10.4110/in.2021.21.e8. eCollection 2021 Feb. Immune Netw. 2021. PMID: 33728101 Free PMC article. Review.
References
- de Alwis R, Williams KL, Schmid MA, Lai CY, Patel B, Smith SA, Crowe JE, Wang WK, Harris E, de Silva AM. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. PLoS Pathog. 2014;10:e1004386. doi: 10.1371/journal.ppat.1004386. - DOI - PMC - PubMed
- Jaume M, Yip MS, Cheung CY, Leung HL, Li PH, Kien F, Dutry I, Callendret B, Escriou N, Altmeyer R, Nal B, Daëron M, Bruzzone R, Peiris JS. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcgammaR pathway. J Virol. 2011;85:10582–10597. doi: 10.1128/JVI.00671-11. - DOI - PMC - PubMed
- Kam YW, Kien F, Roberts A, Cheung YC, Lamirande EW, Vogel L, Chu SL, Tse J, Guarner J, Zaki SR, Subbarao K, Peiris M, Nal B, Altmeyer R. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. Vaccine. 2007;25:729–740. doi: 10.1016/j.vaccine.2006.08.011. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous